APMD (Apnimed) OCF Margin %: -23.36% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

APMD Apnimed Inc APMD
8 GF Score
Price $25.00
View Full Analysis

What is Apnimed OCF Margin %?

Apnimed APMD +13.64% 8 OCF Margin % is -23.36% as of Mar. 2026. GuruFocus rates APMD with a GF Score™ of 8/100. Among 952 Biotechnology companies, Apnimed ranks worse than 105041.91% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Apnimed's Cash Flow from Operations for the three months ended in Mar. 2026 was $-19.81 Mil. Apnimed's Revenue for the three months ended in Mar. 2026 was $84.81 Mil. Therefore, Apnimed's OCF Margin % for the quarter that ended in Mar. 2026 was -23.36%.

As of today, Apnimed's current OCF Yield % is -978,300.00%.

The historical rank and industry rank for Apnimed's OCF Margin % or its related term are showing as below:


APMD's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -64.565
* Ranked among companies with meaningful OCF Margin % only.

Apnimed OCF Margin % Related Terms

Apnimed OCF Margin % Historical Data

* Premium members only.

The historical data trend for Apnimed's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apnimed OCF Margin % Chart

Apnimed Annual Data
Trend Dec24 Dec25
OCF Margin %
-1,375.55 -202.33

Apnimed Quarterly Data
Dec24 Mar25 Dec25 Mar26
OCF Margin % 0.00 -908.72 0.00 -23.36
APMD
8GF Score
Apnimed Inc APMD
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apnimed OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Apnimed's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-77.832/38.467
=-202.33 %

Apnimed's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-19.812/84.814
=-23.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -23.36% mean?
Apnimed (APMD) has a OCF Margin % of -23.36% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Apnimed and its competitors. According to the industry distribution chart, Apnimed ranks #999999 out of 952 companies in the Biotechnology industry.
Is Apnimed's OCF Margin % too high?
Apnimed's current OCF Margin % is -23.36%. Based on the distribution chart, Apnimed ranks #999999 out of 952 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Apnimed has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Apnimed's OCF Margin % compare to ?
According to the Biotechnology industry distribution chart, Apnimed ranks #999999 out of 952 companies for OCF Margin %. This places Apnimed in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Apnimed and its competitors. Apnimed's current OCF Margin % is -23.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apnimed stock overvalued right now?
Apnimed (APMD) has a current OCF Margin % of -23.36%. The current OCF Margin % is -23.36%. Apnimed's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Apnimed (APMD), the current OCF Margin % is -23.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apnimed Business Description

Comparable Companies
Address 39 John F. Kennedy Street, 4th Floor, Cambridge, MA, USA, 02138
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
8GF Score

Get the complete analysis for APMD

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.00
Price